The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome

Status Recruiting

Clinical Trial Summary

The expected results of this study will have a significant impact on the treatment of RLS/WED patients. Magnesium supplementation (if proven to be beneficial) can be utilized as an inexpensive, safer, biologically plausible alternative to dopamine agonists and α2δ calcium-channel ligands.

Clinical Trial Description

This is an open-label, prospective, non-placebo controlled pilot study. 15 subjects with a diagnosis of restless legs syndrome (ICSD-3 diagnostic criteria) will be recruited from OSF Healthcare Saint Francis Medical Center sleep center and Illinois Neurological Institute. RLS/WED patients who meet inclusion and exclusion criteria during the initial clinic visit will be offered study participation. Standard treatment options will be discussed prior to the enrollment. Patients will be reassured that not participating in the study will not affect the future care they receive at OSF HealthCare. The potential risks and benefits of the study will be provided and, if the patient is interested, informed consent will be obtained. If the subject withdraws consent or does not finish both pre and post evaluation, we will replace the subject with another new recruit. The subject will come to the clinic for 2 visits, a pre-magnesium visit and a post-magnesium visit. Following the completion of the pre-magnesium visit, the subject will be given 200 mg elemental magnesium daily (will be instructed to take with food at dinner) for 8 weeks. Both Visits the following study procedures will be performed: magnesium level, (International Restless Legs Syndrome) IRLS scale, Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS-QOL) scale and (Multiple Suggested Immobilization (MSI) test. The post magnesium visit will be schedule at the completion of the 8 week dose of magnesium. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04462796
Study type	Interventional
Source	OSF Healthcare System
Contact	Ashwath R Ravisankar, MBBS
Phone	(309) 624-5422
Email	ashwath.r.ravisankar@osfhealthcare.org
Status	Recruiting
Phase	N/A
Start date	July 10, 2020
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04786314` - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome	N/A
Completed	`NCT01455012` - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome	Phase 4
Terminated	`NCT01192503` - Safety and Efficacy of Rasagiline in Restless Legs Syndrome	Phase 2/Phase 3
Completed	`NCT00530530` - ASP8825 - Study in Patients With Restless Legs Syndrome	Phase 2
Completed	`NCT00721279` - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome	N/A
Completed	`NCT00942253` - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)	Phase 2
Completed	`NCT00375284` - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS	Phase 4
Completed	`NCT00479531` - Sequential Compression Devices for Treatment of Restless Legs Syndrome	Phase 3
Recruiting	`NCT05581576` - Pitolisant in Refractory Restless Legs Syndrome	Phase 4
Active, not recruiting	`NCT03218969` - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist	Phase 1/Phase 2
Recruiting	`NCT04144790` - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed	`NCT05787080` - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)	N/A
Not yet recruiting	`NCT05529095` - Sublingual Apomorphine in Refractory Restless Legs Syndrome	Phase 4
Recruiting	`NCT05044520` - Clinical Features Associated With Restless Legs Syndrome.
Withdrawn	`NCT03849001` - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS	N/A
Completed	`NCT03076541` - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.	N/A
Recruiting	`NCT04145674` - A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo	Phase 2
Completed	`NCT02532608` - Infra-slow Oscillations During Sleep	N/A
Completed	`NCT01528462` - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed	`NCT00748098` - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS) — RLS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms